Announcing the 2nd Annual EU Advanced Therapies Investor Day, November 13 in London! Learn more about the only European financing meeting organized specifically for the sector - providing investors with a unique opportunity to gain insight into the top advanced companies.

The result of this membership merger is the creation of one, global organization operating on behalf of the advanced therapies and regenerative medicine sector (cell therapy, gene therapy and tissue engineering) in both the U.S. and Europe.

Learn more about our three newly established technology sections - Cell Therapy, Gene and Gene-Modified Cell Therapy and Tissue Engineering and Biomaterials - aimed at ensuring that all major technology constituencies within ARM's membership are recognized as primary voices within the organization.

About ARM

Advancing Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations.
Learn more

Our Members

200+ and Growing
ARM’s membership is diverse, representing leading regenerative medicine companies and investors, university-based and non-profit research institutions, patient advocacy groups, pharmaceutical companies engaged in regenerative medicine research and other organizations supporting regenerative medicine.
Learn more